Evidence map›Paper›PMID 36847405›Full record

ArticleJournal of visualized experiments : JoVE2023

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model.

Claudia Manriquez Roman, R Leo Sakemura, Brooke L Kimball, Fang Jin, Roman H Khadka, Mohamad M Adada, Elizabeth L Siegler, Aaron J Johnson, Saad S Kenderian

Erratum issuedAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Claudia Manriquez RomanT Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester; Department of Molecular Medicine, Mayo Clinic, Rochester; Regenerative Sciences PhD Program, Mayo Clinic, Rochester.
R Leo SakemuraT Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester.
Brooke L KimballT Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester.
Fang JinDepartment of Immunology, Mayo Clinic, Rochester.
Roman H KhadkaDepartment of Immunology, Mayo Clinic, Rochester.
Mohamad M AdadaT Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester.
Elizabeth L SieglerT Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester.
Aaron J JohnsonDepartment of Immunology, Mayo Clinic, Rochester.
Saad S KenderianT Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester; Department of Immunology, Mayo Clinic, Rochester; Kenderian.saad@mayo.edu.

Funding

Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid CytokinesR37CA266344 · NCI · MAYO CLINIC ROCHESTER · PI Saad J. Kenderian · 2022 to 2026
$3.5M
Simultaneous Thermal and Osmotic Stresses in Tumor Ablation: Imaging and BiologyR01CA201127 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CRESSMAN, ERIK N · 2016 to 2020
$2.3M
Targeting Cancer-Associated Fibroblasts Prevents Resistance to Chimeric Antigen Receptor T Cell TherapyK99CA273304 · NCI · MAYO CLINIC ROCHESTER · PI SAKEMURA, REONA · 2022 to 2023
$342k
NCI NIH HHS K99 CA273304NCI NIH HHS R01 CA201127NCI NIH HHS R37 CA266344
6 · The paper itself

Abstract

Chimeric antigen receptor T (CART) cell therapy has emerged as a powerful tool for the treatment of multiple types of CD19

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenAnimalsHeterograftsHumansImmunotherapy, AdoptiveMiceReceptors, Antigen, T-CellT-LymphocytesReceptors, Antigen, T-CellReceptors, Chimeric Antigen

Identifiers

PMID36847405
PMCPMC10600946

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.